Cate is a biomedical engineer trained at Imperial College London. She has worked across academia and three neurotechnology startups, driven by a consistent focus on real-world impact and clinical translation. This led her to join Entrepreneurs First and found Aequa.
Implantable neural devices are the gold standard for a growing number of neurological and psychiatric conditions, but only <1% of eligible patients ever receive them, because access requires a neurosurgeon, an operating room, and a willingness to have your skull drilled open. Aequa's mission is to make brain surgery obsolete: delivering single-neuron resolution, with the same precision and efficacy as implants, without a single incision.
Cate is laying the roadmap from scientific breakthrough to clinical translation: initiating regulatory conversations, building commercial foundations, and continuing to advance a preclinical safety programme.
